Human papillomavirus antibody reference reagents for use in postvaccination surveillance serology

Clinical and Vaccine Immunology

Volumn 19, Issue 3, 2012, Pages 449-451

  Bissett, Sara L ^a   Wilkinson, Dianna ^b   Tettmar, Kate I ^c   Jones, Nicky ^b   Stanford, Elaine ^a   Panicker, Gitika ^d   Faust, Helena ^e   Borrow, Ray ^a   Soldan, Kate ^a   Unger, Elizabeth R ^d   Dillner, Joakim ^e   Minor, Philip ^b   Beddows, Simon ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^c NHS BLOOD AND TRANSPLANT   (United Kingdom)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN PAPILLOMAVIRUS ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADULT; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 15; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 3; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 32; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 38; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 5; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN PAPILLOMAVIRUS TYPE 68; HUMAN PAPILLOMAVIRUS TYPE 76; NONHUMAN; PRIORITY JOURNAL; SEROEPIDEMIOLOGY; SEROLOGY; SURVEILLANCE SEROLOGY; VACCINATION; VIRUS NEUTRALIZATION; WART VIRUS;

ADOLESCENT; ANTIBODIES, VIRAL; FEMALE; HUMANS; IMMUNE SERA; PAPILLOMAVIRUS VACCINES; REFERENCE STANDARDS; SEROLOGY;

EID: 84857933930     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05641-11     Document Type: Article

References (21)

1. Brown DR, et al. 2009. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J. Infect. Dis. 199:926-935.
2. Buck CB, Pastrana DV, Lowy DR, Schiller JT. 2005. Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol. Med. 119:445-462.
3. Dessy FJ, et al. 2008. Correlation between direct ELISA, single epitopebased inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum. Vaccin. 4:425-434.
4. Dias D, et al. 2005. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin. Diagn. Lab Immunol. 12:959-969.
5. Draper E, et al. 2011. Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera. Vaccine 29:8585-8590.
6. Faust H, Knekt P, Forslund O, Dillner J. 2010. Validation of multiplexed human papillomavirus serology using pseudovirions bound to heparincoated beads. J. Gen. Virol. 91:1840-1848.
7. Ferguson M, Wilkinson DE, Heath A, Matejtschuk P. 2011. The first international standard for antibodies to HPV 16. Vaccine 29:6520-6526.
8. Frazer IH. 2010. Measuring serum antibody to human papillomavirus following infection or vaccination. Gynecol. Oncol. 118:S8-S11.
9. Harper DM, et al. 2004. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364:1757-1765. (Pubitemid 39488060)
10. Jit M, et al. 2007. Prevalence of human papillomavirus antibodies in young females in England. Br. J. Cancer 97:989-991. (Pubitemid 47519301)
11. Kemp TJ, et al. 2011. HPV16/18 L1 VLP vaccine induces crossneutralizing antibodies that may mediate cross-protection. Vaccine 29: 2011-2014.
12. Kjaer SK, et al. 2009. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev. Res. (Phila.) 2:868-878.
13. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. 2011. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int. J. Cancer 128:927-935.
14. Michael KM, et al. 2008. Seroprevalence of 34 human papillomavirus types in the German general population. PLoS Pathog. 4:e1000091.
15. Paavonen J, et al. 2009. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374:301-314.
16. Plotkin SA. 2008. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis. 47:401-409.
17. Schiller JT, Day PM, Kines RC. 2010. Current understanding of the mechanism of HPV infection. Gynecol. Oncol. 118:S12-S17.
18. Schiller JT, Lowy DR. 2009. Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J. Infect. Dis. 200:166-171.
19. Schiller JT, Lowy DR. 2010. Vaccines to prevent infections by oncoviruses. Annu. Rev. Microbiol. 64:23-41.
20. United Kingdom Department of Health. 2011. Human papillomavirus (HPV). In Salisbury D, Ramsay M, Noakes K (ed), Immunisation against infectious disease - "the green book." HMSO, London, United Kingdom.
21. World Health Organization. 2010. Human papillomavirus laboratory manual, 1st ed, 2009. http://whqlibdoc.who.int/hq/2010/WHO-IVB-10.12 -eng.pdf. World Health Organization, Geneva, Switzerland.